Prescription medicine
Pyrazinamide
Pyrazinamide is a prescription medicine. FDA's NDC Directory lists it from 5 generic labelers, and pharmacies paid $1.31 per pyrazinamide 500 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the pyrazinamide FDA label on DailyMed (effective October 3, 2023, Hikma Pharmaceuticals USA Inc); every pyrazinamide label on DailyMed.
Highlights of the record
FDA label of October 3, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usagePyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
Forms and strengths
- 500 mg
Tablet.
On the market
- Generic approvals
- 3 first June 3, 1971; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 5 of which 5 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $1.31 per tablet Pyrazinamide 500 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 2 since 2022 0 Class I among all firms' recalls; latest May 1, 2023
- FAERS reports
- 9,340 through July 30, 2026
What is pyrazinamide used for?
From the label: indications and usagePyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. […]
FDA pharmacologic class: Antimycobacterial.
Source: FDA drug label (pyrazinamide), Hikma Pharmaceuticals USA Inc, effective October 3, 2023 (SPL set 566db230-3d73-482f-b67d-defd0b2dc46c), via openFDA; the full label on DailyMed
Is there a generic for pyrazinamide?
The FDA approved the first generic pyrazinamide on June 3, 1971. 3 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists pyrazinamide from 5 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for pyrazinamide?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.31 per Pyrazinamide 500 mg tablet, down 45% from $2.38 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Pyrazinamide 500 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Pyrazinamide 500 mg tablet | Generic | $1.31 per tablet | $39.24 | -45% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has pyrazinamide been recalled?
The FDA's Enforcement Report lists 2 recalls naming pyrazinamide since 2022: 0 Class I (the most serious), 2 Class II, 0 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| May 1, 2023 | Class II | RemedyRepack Inc. | CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity … |
| February 15, 2022 | Class II | ANI Pharmaceuticals, Inc. | cGMP Deviations |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the pyrazinamide label say about other medicines?
The pyrazinamide label names no other medicine on this site. The labels of 5 other medicines name pyrazinamide. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
Source: FDA drug label (pyrazinamide), Hikma Pharmaceuticals USA Inc, effective October 3, 2023 (SPL set 566db230-3d73-482f-b67d-defd0b2dc46c), via openFDA; the full label on DailyMed
What do FAERS reports show for pyrazinamide?
The FDA Adverse Event Reporting System holds 9,340 reports that list pyrazinamide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,645 are coded as a death and 4,030 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other antimycobacterials
- the pharmacologic class, with prices and generics
- Pyrazinamide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other